A carregar...
Mortality Benefit of Recombinant Human Interleukin-1 Receptor Antagonist (rhIL1RA) for Sepsis Varies by Initial IL1RA Plasma Concentration
OBJECTIVE: Plasma interleukin-1 beta (IL1β) may influence sepsis mortality, yet recombinant human interleukin-1 receptor antagonist (rhIL1RA) did not reduce mortality in randomized trials. We tested for heterogeneity in the treatment effect of rhIL1RA by baseline plasma IL1β or IL1RA concentration....
Na minha lista:
| Publicado no: | Crit Care Med |
|---|---|
| Main Authors: | , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5734955/ https://ncbi.nlm.nih.gov/pubmed/28991823 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CCM.0000000000002749 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|